Single breath carbon monoxide transfer factor in different forms of chronic airflow obstruction in a general population sample

Ronald J Knudson, Walter T Kaltenborn, Benjamin Burrows

Abstract
The single breath transfer factor for carbon monoxide (TLCO), TLCO/alveolar volume (VA), and standard spirometric indices were measured in a survey of the randomly selected population sample of 1174 subjects enrolled in the Tucson epidemiological study of airways obstructive disease. Subjects were subdivided according to whether the FEV₁/FVC ratio was under 65%, 65-75%, or over 75%. The influence of smoking on TLCO was accounted for by expressing TLCO as a percentage of the expected value—that is, of the value expected from the reported cigarette consumption. The 63 subjects who gave a history of physician confirmed asthma in reply to a questionnaire tended to have high values for TLCO, even when FEV₁/FVC was reduced. In the absence of a given diagnosis of asthma, however, TLCO and TLCO/VA were reduced when the FEV₁/FVC ratio was reduced, whether or not a clinical diagnosis of emphysema had been reported. This suggests that these subjects may have undiagnosed emphysema. This cross sectional analysis of our survey data suggests that subjects in our sample with spirometric evidence of chronic airflow obstruction have different forms of disease, characterised by different physiological features, in addition to the different risk factors and clinical courses reported earlier.

The general term chronic obstructive lung disease is commonly used to describe the condition characterised by persistent airflow obstruction. A primary objective of the Tucson epidemiological study of respiratory health¹ has been to elucidate the nature of chronic airflow obstruction and the associated risk factors. It has become apparent that chronic obstructive lung disease is not a single disease in our population sample and that it may take more than one form. Subjects with asthma appear to develop a different form of disease than cigarette smokers without known asthma. The degree of ventilatory impairment may be similar in all forms of the disease, but the antecedent risk factors, course, and prognosis appear to differ.²³ Subjects with airflow obstruction who report a diagnosis of "asthma" have been shown to share as risk factors atopy, cosinophilia, and a raised serum IgE level. In the absence of such a diagnosis of asthma these risk factors are not significant predictors of airflow obstruction. Subjects with an apparently asthmatic form of severe chronic airways obstruction also appear to have a much better prognosis than those with smoking related "chronic obstructive lung disease." The former appear to have a form of the disease that may be called chronic asthmatic bronchitis, to distinguish it from emphysematous forms of chronic obstructive lung disease.

To determine whether the results of the single breath carbon monoxide transfer factor (TLCO) test differ in subjects with chronic asthmatic bronchitis and in those with other forms of obstructive disease, we examined the results of this test in a randomly selected Tucson community population sample. We also sought to determine whether subjects with airflow obstruction but without a diagnosis of asthma have a low TLCO, consistent with emphysema.

Methods
All subjects had been enrolled in a random, stratified, cluster sample of the white non-Mexican American population of Tucson, Arizona, which is being followed in a prospective epidemiological study of respiratory health.¹ The single breath carbon monoxide transfer factor (TLCO) was measured during the seventh successive survey of the population, beginning in October 1981, and, to maximise participation, also during the following survey, which ended in May 1984. The surveys included standard spirometric testing⁴ and health information obtained from self administered questionnaires. In subjects who had had a recent acute respiratory problem (whether an asthma attack or an acute respiratory illness) at the time of interview, testing was postponed until the subject was back to what he or she regarded as "normal."

TLCO was measured with a Collins APEX DS/420 automated system.⁵ The testing guidelines were those mandated by the Epidemiology Standardisation Project.⁶ Previous analyses had shown that criteria for test acceptability could be broadened to include tests in which inspired volume is at least 85% of a separately determined vital capacity and that one acceptable test result could be used if duplicate results were not available. These broadened criteria maximised the number of results available for analysis without compromising quality. Tests yielded
values for calculation of TLCO in units of ml CO min⁻¹ mm Hg⁻¹ at STPD, alveolar volume (VA, derived from the single breath dilution of inspired helium), expressed in litres BTPS, and the specific transfer factor (TLCO/VA). From the spirometric tests performed at the same time the forced expiratory volume in the first second (FEV₁) and forced vital capacity (FVC) were obtained, the largest value from at least three FVC manoeuvres being selected.

Answers to the self administered questionnaire were used to identify population subgroups. Subjects were considered to have a diagnosis of “asthma,” “emphysema,” or “chronic bronchitis” if on the questionnaire they responded positively to the question of ever having had the disease and affirmed that a doctor had told them they had the condition. Subjects were categorised as “asymptomatic” if they denied having asthma, emphysema, chronic bronchitis, bronchiectasis, dyspnoea on exertion, or attacks of shortness of breath, wheeze, or chest tightness. They also had never had chest (heart or lung) surgery and denied having heart trouble or any neuromuscular, musculoskeletal, or cerebrovascular problem that might affect test performance. Test data from the asymptomatic subjects who also denied ever regularly smoking cigarettes were used to derive our published reference equations for TLCO, VA, and TLCO/VA. On the basis of these equations in this analysis, percentages of predicted values (for example, TLCO % pred) are used to take into account sex, age, and height, but not being a smoker or non-smoker.

In previous analyses the effects of cigarette smoking and of stopping smoking on TLCO were examined in asymptomatic subjects with normal ventilatory function who had smoked cigarettes. From that analysis the following regression equations were derived to yield a % predicted value for TLCO and TLCO/VA that would be expected after taking cumulative cigarette consumption and current smoking into consideration:

\[
\text{Expected TLCO } \% \text{ pred} = 110 - 600 - 4.812 \text{ (pack y)}^{0.4} - 9.714
\]

\[
\text{Expected TLCO/VA } \% \text{ pred} = 107.084 - 4.416 \text{ (pack y)}^{0.6} - 7.350
\]

Cumulative cigarette consumption is expressed as the cube root of pack years of smoking; current smoking decrement, indicated by the asterisk, is subtracted only if the subject is a current smoker. Carbon monoxide back pressure or carboxyhaemoglobin were not measured in this survey, so TLCO in current smokers is likely to be systematically underestimated. This is taken into account, however, by the current smoking decrement in the above equation and thus in the calculation of the expected TLCO or TLCO/VA % pred.

The percentage of the expected value was used in this analysis for TLCO and TLCO/VA to correct for smoking, it being assumed that a significant departure from 100% expected was a consequence of something other than smoking. This concept may be clarified by the following example. A current smoker whose expected TLCO was 80% pred would have a value 100% of that expected if his TLCO was indeed 80% pred. If, however, his TLCO was 60% pred it would be 75% of the expected value, the deficit resulting from a disease that may be caused by smoking but not merely from the fact that he smokes. For a non-smoker the percentage of the expected value is equal to the percentage of the predicted value. This technique adjusts for different smoking habits among groups, but it tends to minimise the apparent decrement in TLCO that may occur in smoking related diseases.

We categorised subjects who failed to meet the questionnaire based criteria for being asymptomatic as “symptomatic,” recognising that this is a non-specific category of people that includes smokers and non-smokers who may or may not have a specific respiratory disease.

Data were analysed on the University of Arizona CDC Cyber 175 computer system with programs from the Statistical Package for the Social Sciences (SPSS version 9.0). Analysis of variance and Duncan’s multiple range test were used to test significance.

**Results**

Questionnaire information, spirometric values, and technically satisfactory measurements of TLCO were obtained on 1174 subjects. Among the subjects who failed to meet the questionnaire based criteria for being free of symptoms or disease that might affect lung function, 17 had had surgical procedures affecting the chest wall or lung resection or had evidence of lung restriction (FVC < 70% pred and FEV₁/FVC > 85%). These were omitted from the analysis. Of the remaining 314 subjects who were categorised as symptomatic, seven said they had both “emphysema” and “asthma.” They appeared to have a more severe form of disease but were too few for useful statistical analysis and were also excluded from the

<table>
<thead>
<tr>
<th>TLCO</th>
<th>FEV₁</th>
<th>Smokers*</th>
</tr>
</thead>
<tbody>
<tr>
<td>% FEV₁/FVC</td>
<td>% predicted</td>
<td>% expected</td>
</tr>
<tr>
<td>&gt;75</td>
<td>97.65 (15.69)</td>
<td>99.86 (15.40)</td>
</tr>
<tr>
<td>65-75</td>
<td>92.19 (16.71)</td>
<td>97.14 (15.93)</td>
</tr>
<tr>
<td>&lt;65</td>
<td>83.39 (22.19)</td>
<td>89.96 (22.31)</td>
</tr>
</tbody>
</table>

*Including ex-smokers. VA—alveolar volume; FEV₁—forced expiratory volume in one second; FVC—forced vital capacity.
analysis. Data from the remaining population sample of 1150 subjects were examined for a relation between TLCO and spirometric variables, and the influence of diagnosis, symptoms, and smoking on these lung function variables.

Because TLCO and TLCO/Va were clearly related to ventilatory function, we have classified the population by severity of airflow obstruction into three groups according to the FEV1/FVC ratio: <65%, 65–75%, and >75%. Mean TLCO and TLCO/Va, expressed as both % predicted and % expected (as defined above), for subjects subdivided by FEV1/VC ratio are shown in table 1. The differences between the % predicted and % expected values reflect the correction for smoking habit and exposure. In the subsequent analyses TLCO and TLCO/Va are expressed as % expected.

The 63 subjects who reported a diagnosis of "asthma" and the remainder of the population were again classified by FEV1/FVC. The influence of a diagnosis of asthma on % expected TLCO are shown in figure 1a. Subjects with a diagnosis of asthma had significantly higher values for TLCO than those without such a diagnosis if the FEV1/FVC was 75%, or more (p = 0.012) or under 65% (p = 0.002); the difference failed to achieve significance in the 65–75% group (p = 0.058). When analysis was confined to the 307 "symptomatic" subjects, (fig 1b) subjects with reported asthma had significantly higher % expected TLCO values (p < 0.01) for all categories of FEV1/FVC. The results were similar when TLCO/Va was used in the analyses shown in these and subsequent figures.

We examined further the influence of smoking by using the % expected TLCO to separate the independent effect of smoking from the effect related to a disease caused by smoking. Subjects with a diagnosis of asthma had well preserved expected TLCO whether or not they smoked. The differences in % expected TLCO between the 23 subjects with a diagnosis of asthma who had smoked and the 40 who had not smoked were not significant either for the total group or when they were grouped by FEV1/FVC. Data from subjects with a diagnosis of asthma, regardless of smoking history, have therefore been compared with the data from non-asthmatic non-smokers and non-asthmatic smokers, data from the entire population sample being used (fig 2). The TLCO % expected was greater in those with a diagnosis of asthma than in non-asthmatic non-smokers (p < 0.05) and smokers (p < 0.01) and the value in non-asthmatic non-smokers was greater than in smokers (p < 0.01).

The same comparisons by FEV1/FVC subgroup are shown in figure 3, which shows that far more subjects with an FEV1/FVC less than 75% had been smokers than non-smokers. The % expected TLCO was significantly greater in subjects given a diagnosis of asthma than in non-asthmatic smokers in all three categories of FEV1/FVC. Although non-asthmatic non-smokers tended to have higher values for % expected TLCO than smokers, the differences
Figure 3 Carbon monoxide transfer factor (TLCO) expressed as percentage of expected value (corrected for smoking) in subjects with diagnosis of "asthma" (regardless of whether they smoked) and non-asthmatic non-smokers and smokers categorised according to %FEV1/FVC ratio. Because values from smokers were not significantly different from those of non-smokers if there was a history of "asthma" results for "asthmatics" and non-asthmatics were combined. Data from all subjects tested are shown.

were not significant when subjects were divided into FEV1/FVC subgroups.

Because the lower % expected TLCO in smokers with diminished ventilatory function (fig 3) led us to suspect that these non-asthmatic subjects may include many with an emphysematous form of airflow obstruction, we examined the relation of respiratory symptoms and other diagnoses to % expected TLCO (table 2). The population was again classified by FEV1/FVC and subjects were divided into the following subgroups: those with a questionnaire based diagnosis of asthma, those who reported a diagnosis of emphysema, those with other respiratory diagnoses or symptoms listed above, those with non-respiratory disorders that placed them in the symptomatic category, and those who met the criteria for being free of symptoms or disease and could be called asymptomatic. Subjects who were considered to be symptomatic because of a non-respiratory disorder included those with heart disease and cerebrovascular, neuromuscular, and musculoskeletal disorders.

When the 21 subjects who reported a diagnosis of "emphysema" were compared with the remainder of the population, they had the lowest values for TLCO (p < 0.01) and poorer ventilatory function than other subgroups. These subjects were distributed throughout all FEV1/FVC subgroups, however (table 2). Of the 53 smokers with an FEV1/FVC of less than 65%, only 11 reported a diagnosis of "emphysema" and their mean % expected TLCO did not differ from that of the remaining 42 (fig 3). Two subjects who reported a diagnosis of "emphysema" appeared among the 463 non-smokers with an FEV1/FVC of 75% or more and a well preserved TLCO.

Finally, we examined the relations between other diagnoses and respiratory symptoms and TLCO. Asymptomatic subjects, on average, had better lung function than those categorized as symptomatic. From answers to the self-administered questionnaire 50% of the population of 1174 subjects tested had dyspnoea on exertion and 4.7% had attacks of shortness of breath with wheeze. Subjects with these complaints had significantly lower % expected TLCO than the remainder of the population. The % expected TLCO in the 5% of the population sample who indicated that they had "chronic bronchitis" did not, however, differ significantly from that of the remainder of the population.

When the analysis was confined to symptomatic subjects, a given diagnosis of asthma or emphysema or both distinguished separate subgroups. When subjects with these diagnoses were excluded from the symptomatic subjects, the % expected TLCO did not distin-

**Table 2** Carbon monoxide transfer factor (TLCO) by categories of ventilatory function and diagnoses and symptoms (mean (SD) values)

<table>
<thead>
<tr>
<th>% FEV1/FVC &gt; 75%</th>
<th>TLCO*</th>
<th>% expected</th>
<th>TLCO/V*</th>
<th>% expected</th>
<th>FEV1/FVC pred</th>
<th>Age (y)</th>
<th>% male</th>
<th>Smokers† No (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Asthma</strong></td>
<td>107.19 (17.46)</td>
<td>107.04 (19.51)</td>
<td>108.01 (13.19)</td>
<td>37.4 (18.7)</td>
<td>29.6 (27.33)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Emphysema</strong></td>
<td>80.51 (19.63)</td>
<td>93.34 (20.85)</td>
<td>98.36 (21.40)</td>
<td>67.0 (7.1)</td>
<td>25.0 (4.00)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other respiratory disorder</td>
<td>97.56 (16.69)</td>
<td>100.99 (14.71)</td>
<td>102.80 (13.68)</td>
<td>52.6 (19.6)</td>
<td>37.5 (48.2)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-respiratory disorder</td>
<td>94.62 (16.32)</td>
<td>98.90 (15.71)</td>
<td>105.11 (14.51)</td>
<td>59.1 (19.3)</td>
<td>35.9 (78.00)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Asymptomatic</strong></td>
<td>100.52 (14.81)</td>
<td>100.45 (14.74)</td>
<td>103.82 (14.62)</td>
<td>38.5 (20.0)</td>
<td>44.8 (36.38)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>% FEV1/FVC 65-75%</strong></td>
<td>104.24 (16.66)</td>
<td>107.58 (15.38)</td>
<td>87.82 (10.88)</td>
<td>42.1 (21.7)</td>
<td>29.4 (41.2)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Asthma</strong></td>
<td>84.63 (20.40)</td>
<td>84.24 (19.06)</td>
<td>98.58 (16.90)</td>
<td>72.7 (9.2)</td>
<td>50.0 (100)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Emphysema</strong></td>
<td>91.08 (16.92)</td>
<td>94.26 (18.93)</td>
<td>93.64 (19.37)</td>
<td>62.7 (18.3)</td>
<td>50.0 (73.7)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other respiratory disorder</td>
<td>94.21 (13.24)</td>
<td>100.22 (16.85)</td>
<td>91.60 (19.00)</td>
<td>68.8 (13.8)</td>
<td>42.5 (62.5)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-respiratory disorder</td>
<td>98.64 (15.80)</td>
<td>97.97 (16.70)</td>
<td>96.21 (13.75)</td>
<td>55.4 (17.2)</td>
<td>50.0 (66.5)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>% FEV1/FVC &lt; 65%</strong></td>
<td>103.51 (17.42)</td>
<td>106.06 (17.15)</td>
<td>65.75 (15.49)</td>
<td>48.8 (19.5)</td>
<td>57.9 (36.8)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Asthma</strong></td>
<td>82.56 (27.33)</td>
<td>81.97 (25.72)</td>
<td>60.44 (24.83)</td>
<td>63.5 (8.6)</td>
<td>63.6 (100)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Emphysema</strong></td>
<td>75.10 (20.90)</td>
<td>77.72 (27.48)</td>
<td>67.35 (16.26)</td>
<td>70.0 (7.9)</td>
<td>70.0 (90.0)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other respiratory disorder</td>
<td>80.56 (18.24)</td>
<td>77.04 (21.68)</td>
<td>77.82 (12.32)</td>
<td>69.3 (13.1)</td>
<td>66.7 (88.9)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-respiratory disorder</td>
<td>91.51 (20.81)</td>
<td>88.18 (20.37)</td>
<td>81.99 (14.06)</td>
<td>61.8 (13.4)</td>
<td>54.1 (37.6)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*The % expected TLCO is significantly (p < 0.05) greater for the group with asthma than for each of the other groups in each category of % FEV1/FVC with the exception of the asymptomatic group with % FEV1/FVC 65-75%. The % expected transfer coefficient (TLCO/V) is significantly greater for the asthma group than for each of the other groups in the %FEV1/FVC < 65% category, significantly greater than for each of the other groups except non-respiratory disorder in the %FEV1/FVC 65-75% category, and significantly greater than for the non-respiratory disorder group and the asymptomatic group in the %FEV1/FVC > 75% category. Duncan's multiple range test was used to test significance.*

†Including ex-smokers.
guish those with exertional dyspnoea or attacks of shortness of breath with wheeze from those without these complaints. In the absence of a specific diagnosis of asthma or emphysema or both, those with other respiratory symptoms or diagnoses did not differ significantly in expected TLco from those who were considered symptomatic because of non-respiratory disease (table 2).

Discussion
In this study a diagnosis of asthma or emphysema was derived from answers to a self administered questionnaire used in an epidemiological study. We do not therefore know the basis for the diagnosis in each case. If we assume that diminished ventilatory function and low TLco are characteristic of emphysema, clearly not all of those who reported this diagnosis fit such a picture. We therefore question the reliability of this diagnostic label. A reported diagnosis of “chronic bronchitis” alone did not appear to distinguish a characteristic subgroup, which is consistent with the observations of Burrows and associates. Although reported symptoms of attacks of shortness of breath with wheeze, as expected, were common among subjects with a diagnosis of asthma, such symptoms in the absence of a diagnosis of asthma did not show the same relation to TLco that was seen in those with such a diagnosis. A reported diagnosis of asthma, alone or in combination with a diagnosis of chronic bronchitis, appeared to distinguish a subgroup with remarkably well preserved TLco. On the basis of the mean % expected value, TLco in subjects with a diagnosis of asthma was well preserved and over 100% of the expected value even if they smoked. Among subjects who had not been given a diagnosis of asthma, however, smokers had a significantly lower TLco than non-smokers, even when TLco was expressed as a percentage of the predicted TLco that would be expected in view of their smoking. This suggests that non-asthmatic smokers may be affected by a disease related to smoking if more non-asthmatic subjects with diminished ventilatory function were smokers than non-smokers, as shown in figure 3. Smoking appears in these subjects to explain both the lower TLco and the decreased ventilatory function. In contrast, subjects with a history of asthma who had a low FEV1/FVC had very well preserved TLco.

If we accept an FEV1/FVC ratio below 65% as indicating chronic obstructive pulmonary disease, our results show that subjects with this level of ventilatory dysfunction who have been given a diagnosis of asthma have significantly higher values for TLco and TLco/VA than subjects without such a history. Earlier analyses of data from our population study have shown that subjects with chronic airflow obstruction who report a diagnosis of asthma form a distinct group who share the risk factors of atopy, eosinophilia, and raised serum IgE levels, with apparently a more benign course of disease than non-asthmatic smokers with airflow obstruction. It now appears that they also share, as a physiological feature of their disease, a well preserved TLco. On the other hand, the risk factors associated with what we may call chronic asthmatic bronchitis are not significant in smokers with airflow obstruction who do not report a diagnosis of asthma. Many of the latter were presumed to have an emphysematous form of chronic obstructive lung disease. From our results, illustrated in figure 3, the non-asthmatic smokers with diminished ventilatory function appear to have a reduced TLco even when this value is corrected for smoking. Only 11 of these 53 subjects reported a diagnosis of emphysema. We believe, therefore, that many of these subjects are likely to have an emphysematous form of airflow obstruction that has not yet received a diagnostic label.

In our subjects with a diagnosis of asthma the TLco and TLco/VA were not only well preserved but, as shown in the tables and figures, above 100% of the expected values and higher than in any other group, including the asymptomatic subjects (p < 0.01). This observation, based on our randomly selected community population sample, is consistent with previous data obtained from patients in clinical or hospital based studies. The physiological changes underlying this association have been investigated. Keens and coworkers found an increase in single breath TLco in normal subjects when the test was carried out with an inspiratory obstruction in the circuit. They suggested that the more negative intrathoracic pressure during inspiration associated with the airway obstruction increased pulmonary capillary blood volume (Vc). Stewart measured pulmonary capillary blood volume in healthy subjects and asthmatic patients with mild airflow obstruction and found TLco and Vc/VA to be higher in the asthmatic group and to increase with increasing airflow obstruction. These observations may explain the increased TLco associated with asthma that we and others have observed.

In summary, subjects in our population sample who show chronic airflow obstruction appear to have different forms of disease, characterised by different physiological features, as well as different risk factors and clinical courses. The single breath carbon monoxide transfer factor was well preserved or raised in subjects given a diagnosis of asthma even when ventilatory function was impaired. On the other hand, most subjects with chronic airflow obstruction and reduced TLco were cigarette smokers without a diagnosis of asthma. They are likely to include many with an emphysematous form of disease.

We would like to express appreciation to Warren E Collins Inc for providing the equipment used in this study and gratefully acknowledge the assistance of B Boyer and the Arizona SCOR epidemiological field staff for data gathering, and A Reeves in preparing the manuscript, and of the hundreds of citizens of Tucson, Arizona, whose willing cooperation made the study possible.
Single breath carbon monoxide transfer factor in different forms of chronic airflow obstruction in a general population sample

8 Evans CG, Ogilvie CM. Transfer factor in asthma. Lancet 1970;ii:591.
Single breath carbon monoxide transfer factor in different forms of chronic airflow obstruction in a general population sample.

R J Knudson, W T Kaltenborn and B Burrows

Thorax 1990 45: 514-519
doi: 10.1136/thx.45.7.514

Updated information and services can be found at:
http://thorax.bmj.com/content/45/7/514

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/